MarginsXMarginsX
Home › Markets › Health Care › AUPH

Aurinia Pharmaceuticals Inc (AUPH)

AUPH trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$15.48
-1.59% on the day
Market cap
$2.1B
Mid cap
Revenue · 2025
$283.1M
+20.4% on 2024
Net income · 2025
$287.2M
101.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1600620/000160062026000017/0001600620-26-000017-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerAUPH on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryCanada
IPO yearNot reported by the screener
SEC CIK0001600620
SEC industry codePharmaceutical Preparations
Incorporated inALBERTA, CANADA

Financials · 2025

LineValue
Revenue$283.1M
Net income$287.2M
Operating income$104.9M
Net margin101.5%
Operating margin37.1%
Revenue growth+20.4%
Cash$80.2M
Total assets$751.6M
P/E (computed)7.2×
P/S (computed)7.3×

Warning signs

Cash runway
Cash-flow positive
$45.8M cash at September 30, 2026
Share count, 1 year
+1.6%
2025-11-03 to 2026-10-29 · -6.7% over 3 years
Going-concern doubt
No
10-Q filed October 30, 2026
Insider net buying, 12 months
$24.6M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-30
Cash and burn$45.8M cash; operating cash flow $44.3M a quarter.Report 2026-09-30
Shares outstanding133,998,660 (2026-10-29); 131,840,559 a year earlier; 143,608,164 three years earlier.Cover page 2026-10-29
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Edmonton, CanadaPCAOB Form AP 2026-03-19
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $25.1M, sold $546K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$83.7M$31.7M$46.4M$45.8MNo debt tags$321.7M10-Q 2026-10-30
Q2 2026
2026-06-30
$83.2M$37.4M$52.6M$179.7MNo debt tags$311.5M10-Q 2026-08-06
Q1 2026
2026-03-31
$77.7M$34.4M$32.6M$40.7MNo debt tags$298.3M10-Q 2026-05-07
Q4 2025
2025-12-31
$77.1M$210.8M$45.7M$80.2MNo debt tags$283.1M10-K 2026-02-26
Q3 2025
2025-09-30
$73.5M$31.6M$44.4M$72.9MNo debt tags$265.8M10-Q 2026-10-30
Q2 2025
2025-06-30
$70.0M$21.5M$44.2M$52.9MNo debt tags$260.1M10-Q 2026-08-06
Q1 2025
2025-03-31
$62.5M$23.3M$1.3M$66.1MNo debt tags$247.3M10-Q 2026-05-07
Q4 2024
2024-12-31
$59.9M$1.4M$30.1M$83.4MNo debt tags$235.1M10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2021-11-19
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-10-30
Latest current report8-K2026-10-30
Latest proxyDEF 14A2026-04-21

Source: SEC EDGAR submissions feed, 615 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-4.4%
1 month-3.9%
3 months+3.6%
Year to date-1.4%
1 year+3.4%
From 52-week high-15.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
IMNMImmunome Inc.$17.61-6.18%$2.1B
BHVNBiohaven Ltd. Common Shares$13.80-0.14%$2.1B
SDGRSchrodinger Inc.$27.36-7.35%$2.1B
PVLAPalvella Therapeutics Inc.$144.60-5.17%$2.1B
SEPNSepterna Inc.$41.67-2.18%$2.0B
TRAXFirst Tracks Biotherapeutics Inc. Ordinary Shares$46.56-1.15%$2.0B
VERAVera Therapeutics Inc.$26.97-4.02%$1.9B
HRMYHarmony Biosciences Holdings Inc.$32.96-2.37%$1.9B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier